The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis

被引:0
|
作者
Radic, M. [1 ]
Kaliterna, D. Martinovic [1 ]
Ljutic, D. [1 ]
机构
[1] Clin Hosp Split, Dept Internal Med, Split, Croatia
关键词
systemic sclerosis; anti-topoisomerase I antibody; contracture;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background It is found that an antibody directed against DNA topoisomerase I (anti-topo I abs) is detected almost exclusively in systemic sclerosis (SSc). These antibodies are predictors of pulmonary fibrosis and peripheral vascular disease. Objective Metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints flexion contractures are assessed as markers of active SSc. The aim of this study was to find out is there any relationship between anti-topo I abs and MCP and PIP joints flexion contractures. Methods Twenty-eight patients with active disease who fulfilled the American College of Rheumatology criteria for SSc were included in this study. Twenty eight healthy control subjects were also investigated. Clinical and radiological assessments of the hands were carried out. The flexion ranges in the 8 finger joints by goniometric measurement were obtained. Anti-topo I abs with an enzyme linked immunosorbent assay (ELISA) were measured. Results MCP and PIP joints flexion contractures and the levels of anti-topo I abs were significantly higher in patients with systemic sclerosis than in healthy control. The anti-topo I abs were found in 16 of 28 patients with systemic sclerosis. Sixteen of 28 patients with active disease had MPC and proximal PIP joints flexion contractures. In 16 SSc patients with anti-topo I abs, 13 had metacarpophalangeal and proximal interphalangeal joints flexion contractures. In only 3 patients of 16 with the flexion contractures the levels of anti-topo I abs were negative. The patients with MPC and PIP joints flexion contractures had higher mean value of anti-topo I abs titers (53.718 +/- 50.977 vs 8.127 +/- 8.915, P < 0.0001) than did those with no contractures. Furthermore, the titers of anti-topo isomerase I antibody positively correlated with the flexion contractures (r = 0.4252, P = 0.0241). Radiologically, joint space narrowing and flexion contractures of the fingers were seen significantly more frequently in the SSc patients with anti-topo I abs (P < 0.05). Conclusion Serum level of anti-topoisomerase I antibodies is in direct relationship with MPC and PIP joints flexion contractures.
引用
收藏
页码:407 / 412
页数:6
相关论文
共 50 条
  • [41] Anti-topoisomerase 1 Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis
    Ananyeva, L. P.
    Garzanova, L. A.
    Koneva, O. A.
    Starovoytova, M. N.
    Desinova, O. V.
    Ovsyannikova, O. B.
    Shayakhmetova, R. U.
    Cherkasova, M. V.
    Aleksankin, A. P.
    Nasonov, E. L.
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2023, 511 (01) : 212 - 218
  • [42] Ethnic background influences clinical and serologic features in systemic sclerosis (SSc) patients with anti-topoisomerase I (TOPO I) antibody.
    Kuwana, M
    Kaburaki, J
    Amett, FC
    Medsger, TA
    Wright, TM
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 421 - 421
  • [43] Longitudinal Follow-up of Anti-Topoisomerase I Positive Patients within the Leiden Systemic Sclerosis Cohort - Prognosis Infaust?
    Boonstra, Maaike
    Ninaber, Maarten K.
    Marsan, Nina Ajmone
    Scherer, Hans U.
    Huizinga, Tom W. J.
    de Vries-Bouwstra, Jeska
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [44] Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody
    Perera, Achini
    Fertig, Noreen
    Lucas, Mary
    Rodriguez-Reyna, Tatiana S.
    Hu, Paul
    Steen, Virginia D.
    Medsger, Thomas A., Jr.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (08): : 2740 - 2746
  • [45] Coexistence of anti-topoisomerase I and anticentromere antibodies in a patient with systemic sclerosis. Efficacy of treatment combining rituximab and nintedanib. A case report
    Montolio-Chiva, Lydia
    Carmona-Talavera, Diego
    Lopez-Ortega, Jose M.
    Orenes-Vera, Ana V.
    Flores-Fernandez, Eduardo
    Alegre-Sancho, Juan J.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2022, 36
  • [46] Effects of serial casting in the treatment of flexion contractures of proximal interphalangeal joints in patients with rheumatoid arthritis and juvenile idiopathic arthritis: A retrospective study
    Ugurlu, Umit
    Ozdogan, Huri
    JOURNAL OF HAND THERAPY, 2016, 29 (01) : 41 - 50
  • [47] Factors associated with disease course in systemic sclerosis patients with anti-topoisomerase-I antibodies.
    Perera, A
    Lucas, M
    Fertig, N
    Hu, P
    Medsger, TA
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S562 - S562
  • [48] Association of Fcγ receptor IIIA variant with a subset of anti-topoisomerase I-positive patients in systemic sclerosis: a descriptive pilot study
    Magnant, J.
    Ohresser, M.
    Allanore, Y.
    de Monte, M.
    Lafosse-Marin, M.
    Degenne, D.
    Guilmot, J. L.
    Watier, H.
    Diot, E.
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (07) : 2203 - 2207
  • [49] Association of Fcγ receptor IIIA variant with a subset of anti-topoisomerase I-positive patients in systemic sclerosis: a descriptive pilot study
    J. Magnant
    M. Ohresser
    Y. Allanore
    M. de Monte
    M. Lafosse-Marin
    D. Degenne
    J. L. Guilmot
    H. Watier
    E. Diot
    Rheumatology International, 2012, 32 : 2203 - 2207
  • [50] IgM, IgG, and IgA Anti-DNA Topoisomerase I Antibodies in Systemic Sclerosis
    Martinez-Cordero, Erasmo
    Padilla Trejo, Alejandro
    Aguilar Leon, Diana E.
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2009, 23 (06) : 408 - 416